Current Environment: Production

Medical Services

Specialties

Programs & Services

Education

Undergraduate School

Boston University

1999, Boston, MA

Medical School

Boston University School of Medicine

2003, Boston, MA

Residency

Pediatrics

University of California, San Francisco Medical Center

2006, San Francisco, CA

Fellowship

Boston Children's Hospital/Dana-Farber Cancer Institute

Pediatric Hematology-Oncology Program

Boston, MA

Publications

  1. Emerging Role of Blood-based Biomarkers in Sarcomas. Hematol Oncol Clin North Am. 2025 May 22. View Abstract

  2. Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients. medRxiv. 2025 May 14. View Abstract

  3. Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. medRxiv. 2025 Jan 20. View Abstract

  4. Rare germline structural variants increase risk for pediatric solid tumors. Science. 2025 01 03; 387(6729):eadq0071. View Abstract

  5. Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). J Clin Oncol. 2025 Apr; 43(10):1188-1197. View Abstract

  6. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 Jul; 25(7):912-921. View Abstract

  7. Rare germline structural variants increase risk for pediatric solid tumors. bioRxiv. 2024 Apr 29. View Abstract

  8. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. Blood. 2024 04 11; 143(15):1513-1527. View Abstract

  9. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. Commun Biol. 2024 04 08; 7(1):426. View Abstract

  10. Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. JAMA Netw Open. 2024 03 04; 7(3):e244170. View Abstract

  11. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial. Ann Oncol. 2024 Jun; 35(6):559-568. View Abstract

  12. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q. Nat Commun. 2023 12 18; 14(1):8006. View Abstract

  13. Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatr Blood Cancer. 2023 Dec; 70(12):e30681. View Abstract

  14. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 2023 07; 12(14):15207-15216. View Abstract

  15. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA. Clin Cancer Res. 2023 05 01; 29(9):1689-1697. View Abstract

  16. The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q Study. Res Sq. 2023 Mar 16. View Abstract

  17. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334. View Abstract

  18. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 05 01; 41(13):2382-2393. View Abstract

  19. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 04 10; 41(11):2098-2107. View Abstract

  20. Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors. Pediatr Blood Cancer. 2023 05; 70 Suppl 2:e30130. View Abstract

  21. Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. Br J Cancer. 2022 12; 127(12):2220-2226. View Abstract

  22. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17; 6(1):65. View Abstract

  23. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. Eur J Cancer. 2022 Sep; 172:264-275. View Abstract

  24. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. View Abstract

  25. Serrated Polyposis Syndrome in a Young Adolescent Patient. J Pediatr Gastroenterol Nutr. 2022 09 01; 75(3):e49-e52. View Abstract

  26. Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clin Cancer Res. 2022 06 13; 28(12):2579-2586. View Abstract

  27. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clin Cancer Res. 2022 06 01; 28(11):2397-2408. View Abstract

  28. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. J Clin Oncol. 2022 09 10; 40(26):3047-3056. View Abstract

  29. Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. Am J Hum Genet. 2022 06 02; 109(6):1026-1037. View Abstract

  30. Rapid and highly sensitive approach for multiplexed somatic fusion detection. Mod Pathol. 2022 08; 35(8):1022-1033. View Abstract

  31. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5. View Abstract

  32. Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. Arch Pathol Lab Med. 2021 12 01; 145(12):1564-1568. View Abstract

  33. STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. Cancer Cell. 2021 06 14; 39(6):827-844.e10. View Abstract

  34. Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer. 2020 09; 67(9):e28326. View Abstract

  35. Using Liquid Biopsy in the Treatment of Patient with OS. Adv Exp Med Biol. 2020; 1257:95-105. View Abstract

  36. EWS-FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex. Nucleic Acids Res. 2019 10 10; 47(18):9619-9636. View Abstract

  37. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 10 15; 125(20):3514-3525. View Abstract

  38. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. Clin Cancer Res. 2019 07 15; 25(14):4552-4566. View Abstract

  39. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869. View Abstract

  40. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View Abstract

  41. Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease. JCO Precis Oncol. 2019; 2019. View Abstract

  42. Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. JCO Precis Oncol. 2019; 3. View Abstract

  43. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatr Blood Cancer. 2019 05; 66(5):e27595. View Abstract

  44. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621. View Abstract

  45. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Mol Cancer Ther. 2018 09; 17(9):1902-1916. View Abstract

  46. Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018. View Abstract

  47. Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients. PLoS One. 2017; 12(12):e0188835. View Abstract

  48. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer. 2016 11; 63(11):1974-82. View Abstract

  49. Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 06 22; 7:11987. View Abstract

  50. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View Abstract

  51. Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet. 2016 05; 209(5):182-94. View Abstract

  52. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma. Oncotarget. 2015 Oct 06; 6(30):30178-93. View Abstract

  53. CSF 5-Methyltetrahydrofolate Serial Monitoring to Guide Treatment of Congenital Folate Malabsorption Due to Proton-Coupled Folate Transporter (PCFT) Deficiency. JIMD Rep. 2015; 24:91-6. View Abstract

  54. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. J Clin Invest. 2014 Dec; 124(12):5275-90. View Abstract

  55. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014 Nov; 4(11):1326-41. View Abstract

  56. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218. View Abstract

  57. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013 May 01; 73(9):2873-83. View Abstract

  58. Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter. Clin Immunol. 2009 Dec; 133(3):287-94. View Abstract

  59. Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr Blood Cancer. 2006 Sep; 47(3):255-9. View Abstract
BESbswy